TEK2day FINANCE Open Terminal →

Charles River Laboratories International, Inc. (CRL)

NYQ · Healthcare · Diagnostics & Research

$187.51 -0.29%

Closing price as of 2026-06-12 · Source: TEK2day Finance

1-Year Price History +23.5% over period
$231$208$186$163$141 2025-062025-092025-122026-032026-06

Key Metrics

Market Cap
$9.03B
Shares Outstanding
48.2M
P/S (TTM)
2.2x
Exchange
NYQ
Currency
USD

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Quarterly Financials

Metric2025-06-302025-09-302025-12-312026-03-31
Revenue1.0B1.0B994.2M995.8M
Gross Profit357.1M338.8M309.7M294.7M
Operating Income100.1M133.8M92.5M119.9M
Net Income52.3M54.4M-276.6M-14.8M
Diluted EPS$1.06$1.10$-5.62$-0.30

Annual Financials

Metric2022-12-312023-12-312024-12-312025-12-31
Revenue4.0B4.1B4.0B4.0B
Gross Profit1.5B1.5B1.3B1.3B
Operating Income651.0M617.3M442.3M401.1M
Net Income486.2M474.6M10.3M-144.3M
Diluted EPS$9.48$9.22$0.20$-2.91
Want live quotes, estimates, SEC filings, and CEO analytics for CRL?
The free TEK2day terminal runs in your browser — type /CRL to get started.
Open CRL in the Terminal →